Interview Summary	Application No.	Applicant(s)	
	10/623,119	ANDERSSON ET AL.	
	Examiner	Art Unit	
	Celia Chang	1625	

All participants (applicant, applicant's representative, PTO personnel):

(1) *Celia Chang*. (3)_____.

(2) *Daniel Hart*. (4)_____.

Date of Interview: *14 February 2007*.

Type: a)☒ Telephonic b)☐ Video Conference
c)☐ Personal [copy given to: 1)☐ applicant 2)☐ applicant's representative]

Exhibit shown or demonstration conducted: d)☐ Yes e)☐ No.
If Yes, brief description: _____.

Claim(s) discussed: *1,5,18 and 22*.

Identification of prior art discussed: _____.

Agreement with respect to the claims f)☒ was reached. g)☐ was not reached. h)☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: *the term heteroalkyl is replaced by the explicit disclosure found on pages 10-12. Au examiner's amendment was authorized*.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

Examiner's signature, if required

Summary of Record of Interview Requirements

Manual of Patent Examining Procedure (MPEP), Section 713.04, Substance of Interview Must be Made of Record
A complete written statement as to the substance of any face-to-face, video conference, or telephone interview with regard to an application must be made of record in the application whether or not an agreement with the examiner was reached at the interview.

Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews
Paragraph (b)
In every instance where reconsideration is requested in view of an interview with an examiner, a complete written statement of the reasons presented at the interview as warranting favorable action must be filed by the applicant. An interview does not remove the necessity for reply to Office action as specified in §§ 1.111, 1.135. (35 U.S.C. 132)

37 CFR §1.2 Business to be transacted in writing.
All business with the Patent or Trademark Office should be transacted in writing. The personal attendance of applicants or their attorneys or agents at the Patent and Trademark Office is unnecessary. The action of the Patent and Trademark Office will be based exclusively on the written record in the Office. No attention will be paid to any alleged oral promise, stipulation, or understanding in relation to which there is disagreement or doubt.

The action of the Patent and Trademark Office cannot be based exclusively on the written record in the Office if that record is itself incomplete through the failure to record the substance of interviews.

It is the responsibility of the applicant or the attorney or agent to make the substance of an interview of record in the application file, unless the examiner indicates he or she will do so. It is the examiner's responsibility to see that such a record is made and to correct material inaccuracies which bear directly on the question of patentability.

Examiners must complete an Interview Summary Form for each interview held where a matter of substance has been discussed during the interview by checking the appropriate boxes and filling in the blanks. Discussions regarding only procedural matters, directed solely to restriction requirements for which interview recordation is otherwise provided for in Section 812.01 of the Manual of Patent Examining Procedure, or pointing out typographical errors or unreadable script in Office actions or the like, are excluded from the interview recordation procedures below. Where the substance of an interview is completely recorded in an Examiners Amendment, no separate Interview Summary Record is required.

The Interview Summary Form shall be given an appropriate Paper No., placed in the right hand portion of the file, and listed on the "Contents" section of the file wrapper. In a personal interview, a duplicate of the Form is given to the applicant (or attorney or agent) at the conclusion of the interview. In the case of a telephone or video-conference interview, the copy is mailed to the applicant's correspondence address either with or prior to the next official communication. If additional correspondence from the examiner is not likely before an allowance or if other circumstances dictate, the Form should be mailed promptly after the interview rather than with the next official communication.

The Form provides for recordation of the following information:
- Application Number (Series Code and Serial Number)
- Name of applicant
- Name of examiner
- Date of interview
- Type of interview (telephonic, video-conference, or personal)
- Name of participant(s) (applicant, attorney or agent, examiner, other PTO personnel, etc.)
- An indication whether or not an exhibit was shown or a demonstration conducted
- An identification of the specific prior art discussed
- An indication whether an agreement was reached and if so, a description of the general nature of the agreement (may be by attachment of a copy of amendments or claims agreed as being allowable). Note: Agreement as to allowability is tentative and does not restrict further action by the examiner to the contrary.
- The signature of the examiner who conducted the interview (if Form is not an attachment to a signed Office action)

It is desirable that the examiner orally remind the applicant of his or her obligation to record the substance of the interview of each case. It should be noted, however, that the Interview Summary Form will not normally be considered a complete and proper recordation of the interview unless it includes, or is supplemented by the applicant or the examiner to include, all of the applicable items required below concerning the substance of the interview.

A complete and proper recordation of the substance of any interview should include at least the following applicable items:
1) A brief description of the nature of any exhibit shown or any demonstration conducted,
2) an identification of the claims discussed,
3) an identification of the specific prior art discussed,
4) an identification of the principal proposed amendments of a substantive nature discussed, unless these are already described on the Interview Summary Form completed by the Examiner,
5) a brief identification of the general thrust of the principal arguments presented to the examiner,
   (The identification of arguments need not be lengthy or elaborate. A verbatim or highly detailed description of the arguments is not required. The identification of the arguments is sufficient if the general nature or thrust of the principal arguments made to the examiner can be understood in the context of the application file. Of course, the applicant may desire to emphasize and fully describe those arguments which he or she feels were or might be persuasive to the examiner.)
6) a general indication of any other pertinent matters discussed, and
7) if appropriate, the general results or outcome of the interview unless already described in the Interview Summary Form completed by the examiner.

Examiners are expected to carefully review the applicant's record of the substance of an interview. If the record is not complete and accurate, the examiner will give the applicant an extendable one month time period to correct the record.

Examiner to Check for Accuracy

If the claims are allowable for other reasons of record, the examiner should send a letter setting forth the examiner's version of the statement attributed to him or her. If the record is complete and accurate, the examiner should place the indication, "Interview Record OK" on the paper recording the substance of the interview along with the date and the examiner's initials.

AMENDMENTS TO THE CLAIMS

1. (CURRENTLY AMENDED) A compound of formula (I):



(I)

wherein:

Z_1 is CR_1, Z_2 is CR_2, Z_3 is CR_3, and Z_4 is CR_4;

W_1 is [[O,]] S[[, or NR_5]], W_2 is N or CR_6, and W_3 is CG; ~~W_1 is NG, W_2 is CR_5 or N, and W_3 is CR_6 or N;~~

G is of formula (II):



(II)

Y is O, S, CHOH, -NHC(O)-, -C(O)NH-, -C(O)-, -OC(O)-, -(O)CO-, $-NR_7$-, -CH=N-, or absent;

p is 1, 2, 3, 4 or 5;

Z is CR_8R_9 or absent;

each t is 1, 2, or 3;

each R_1, R_2, R_3, and R_4, independently, is H. amino, hydroxyl, halo, or straight- or branched-chain C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, ~~C_{1-6} heteroalkyl,~~ C_{1-6} haloalkyl, -CN, $-CF_3$, $-OR_{11}$, $-COR_{11}$, $-NO_2$, $-SR_{11}$, $-NHC(O)R_{11}$, $-C(O)NR_{12}R_{13}$, $-NR_{12}R_{13}$, $-NR_{11}C(O)NR_{12}R_{13}$, $-SO_2NR_{12}R_{13}$, $-OC(O)R_{11}$, $-O(CH_2)_qNR_{12}R_{13}$, or $-(CH_2)_qNR_{12}R_{13}$, where q is an integer from 2 to 6, or R_1 and R_2 together form -NH-N=N- or R_3 and R_4 together form -NH-N=N-; methoxymethyl, ethoxymethyl, propoxymethyl

each R_5, R_6, and R_7, independently, is H, C_{1-6} alkyl; formyl; C_{3-6} cycloalkyl; C_{5-6} aryl, optionally substituted with halo or C_{1-6} alkyl; or C_{5-6} heteroaryl, optionally substituted with halo or C_{1-6} alkyl;

each R_8 and R_9, independently, is H or straight- or branched-chain C_{1-8} alkyl;

R_{10} is [[H,]] straight- or branched-chain C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-8} alkylidene, C_{1-8} alkoxy, or ~~C_{1-8} heteroalkyl, C_{1-8} aminoalkyl, C_{1-8} haloalkyl, C_{1-8} alkoxycarbonyl, C_{1-8} hydroxyalkoxy, C_{1-8} hydroxyalkyl, SH, C_{1-8} alkylthio, O-CH_2-C_{5-6} aryl, C(O)-C_{5-6} aryl~~ methoxymethyl, ethoxymethyl, propoxymethyl

~~substituted with C_{1-3} alkyl or halo, C_{5-6} aryl, C_{5-6} cycloalkyl, C_{5-6} heteroaryl, C_{5-6} heterocycloalkyl, $NR_{12}R_{13}$, $C(O)NR_{12}R_{13}$, $NR_{11}C(O)NR_{12}R_{13}$, $CR_{11}R_{12}R_{13}$, $OC(O)R_{11}$, $(O)(CH_2)_sNR_{12}R_{13}$ or $(CH_2)_sNR_{12}R_{13}$, s being an integer from 2 to 8~~;

R_{10}' is H, straight- or branched-chain C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-8} alkylidene, C_{1-8} alkoxy, ~~C_{1-8} heteroalkyl,~~ methoxymethyl, ethoxymethyl, propoxymethyl C_{1-8} aminoalkyl, C_{1-8} haloalkyl, C_{1-8} alkoxycarbonyl, C_{1-8} hydroxyalkoxy, C_{1-8} hydroxyalkyl, or C_{1-8} alkylthio;

each R_{11}, independently, is H, straight- or branched-chain C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, ~~C_{2-8} heteroalkyl,~~ methoxymethyl, ethoxymethyl, propoxymethyl C_{2-8} aminoalkyl, C_{2-8} haloalkyl, C_{1-8} alkoxycarbonyl, C_{2-8} hydroxyalkyl, -C(O)-C_{5-6} aryl substituted with C_{1-3} alkyl or halo, C_{5-6} aryl, C_{5-6} heteroaryl, C_{5-6} cycloalkyl, C_{5-6} heterocycloalkyl, $-C(O)NR_{12}R_{13}$, $-CR_5R_{12}R_{13}$, $-(CH_2)_tNR_{12}R_{13}$, t is an integer from 2 to 8; and

each R_{12} and R_{13}, independently, is H, C_{1-6} alkyl; C_{3-6} cycloalkyl; C_{5-6} aryl, optionally substituted with halo or C_{1-6} alkyl; or C_{5-6} heteroaryl, optionally substituted with halo or C_{1-6} alkyl; ~~or R_{12} and R_{13} together form a cyclic structure;~~

or a pharmaceutically acceptable salt, ester or prodrug thereof.

2. (CURRENTLY AMENDED) The compound of claim 1, wherein each t is 2 ~~and R_{10} is straight- or branched-chain C_{2-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-8} alkylidene, C_{1-8} alkoxy, or C_{1-8} heteroalkyl~~.

3. (ORIGINAL) The compound of claim 2, wherein R_{10} is n-butyl.

4. (CANCELED)

4 5. (PREVIOUSLY PRESENTED) The compound of claim 2, wherein each R_1, R_2, R_3, and R_4, independently, is H, hydroxyl, halo, ~~C_{1-8} heteroalkyl,~~ methoxymethyl, ethoxymethyl, propoxymethyl CF_3, $-NO_2$, or straight- or branched-chain C_{1-6} alkyl, or R_1 and R_2 together form -NH-N=N- or R_3 and R_4 together form -NH-N=N-.

5 6. (ORIGINAL) The compound of claim 2, wherein Y is absent or O, p is 0, 1, 2 or 3, and R_8 and R_9 are H.

6 7. (ORIGINAL) The compound of claim 6, wherein Z is absent, Y is absent and p is 3.

7 8. (ORIGINAL) The compound of claim 7, wherein R_{10} is n-butyl.

9-16. (CANCELED)

8 VI. (CURRENTLY AMENDED) The compound of claim 1, wherein the compound is:

~~1-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indole;~~

~~1-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-benzoimidazole;~~

~~3-methyl-1-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indole;~~

~~5-bromo-1-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indole;~~

~~3-formyl-1-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indole;~~

~~7-bromo-1-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indole;~~

~~3-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-benzo[*d*]isoxazole;~~

~~3-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indole;~~

~~3-(2-(4-*n*-butylpiperidine)-1-yl-ethyl)-1*H*-indole;~~

~~3-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indazole;~~

~~3-(2-(4-n-butylpiperidine)-ethoxy)-7-methyl-benzo[*d*]isoxazole;~~

~~1-(3-(4-methylpiperidine)-1-yl-propyl)-1H-indazole;~~

~~1-(3-(4-pentylpiperidine)-1-yl-propyl)-1H-indazole;~~

~~1-(3-(4-propylpiperidine)-1-yl-propyl)-1H-indazole;~~

~~1-(3-(4-(3-methyl-butyl)-piperidine)-1-yl-propyl)-1H-indazole~~

~~1-(3-(4-pentylidene-piperidine)-1-yl-propyl)-1H-indazole;~~

~~1-(3-(4-propylidene-piperidine)-1-yl-propyl)-1H-indazole~~

1-benzo[*b*]thiophen-2-yl-4-(4-butylpiperidin-1-yl)-butan-1-one

~~4-(4-butylpiperidin-1-yl)-1-(3-methyl-benzofuran-2-yl)-butan-1-one;~~

4-(4-butylpiperidin-1-yl)-1-(5-fluoro-3-methyl-benzo[*b*]thiophen-2-yl)-butan-1-one;

~~1-benzofuran-2-yl-4-(4-butylpiperidin-1-yl)-butan-1-one;~~

1-(3-bromo-benzo[*b*]thiophen-2-yl)-4-(4-butylpiperidin-1-yl)-butan-1-one

1-(3-benzo[*b*]thiophen-2-yl-propyl)-4-butylpiperidine;

~~1-(3-benzofuran-2-yl-propyl)-4-butylpiperidine;~~

~~4-butyl-1-[3-(3-methyl-benzofuran-2-yl)-propyl]-piperidine;~~

4-butyl-1-[3-(5-fluoro-3-methyl-benzo[*b*]thiophen-2-yl)-propyl]-piperidine;

~~2-(3-iodo-propyl)-benzo[*b*]thiophene;~~

1-(3-benzo[*b*]thiophen-2-yl-propyl)-4-methylpiperidine

1-(3-benzo[*b*]thiophen-2-yl-propyl)-4-benzylpiperidine; or

~~1-(3-benzo[*b*]thiophen-2-yl-propyl)-4-(2-methoxy-phenyl)-piperidine;~~

~~1-[3-(4-butylpiperidin-1-yl)-propyl]-1H-benzotriazole;~~

~~1-[3-(4-butylpiperidin-1-yl)-propyl]-1*H*-indole-3-carbaldehyde;~~

~~{1-[3-(4-butylpiperidin-1-yl)-propyl]-1H-indol-3-yl}-methanol;~~

~~1-[3-(4-butylpiperidin-1-yl)-propyl]-2-phenyl-1*H*-benzoimidazole;~~

~~1-[3-(4-butylpiperidin-1-yl)-propyl]-3-chloro-1*H*-indazole;~~

~~1-[3-(4-butylpiperidin-1-yl)-propyl]-6-nitro-1*H*-indazole;~~

~~3-[2-(4-butylpiperidin-1-yl)-ethoxy]-benzo[*d*]isoxazol;~~

~~3-[3-(4-butyl-piperidin-1-yl)-propyl]-1*H*-indole hydrochloride;~~

~~1H-indazole-3-carboxylic acid-(2-(4-butylpiperidin)-1-yl-ethyl)-amide;~~

~~1-[3-(4-butylpiperidin-1-yl)-propyl]-5-nitro-1H-indazole;~~

~~1-[3-(4-butyl-piperidin-1-yl)-propyl]-2-methyl-1*H*-indole;~~

~~1-{1-[3-(4-butyl-piperidin-1-yl)-propyl]-1H-indol-3-yl}-ethanone;~~

~~{1-[3-(4-butyl-piperidin-1-yl)-propyl]-1H-indol-3-yl}-acetonitrile;~~

~~1-[3-(4-butyl-piperidin-1-yl)-propyl]-1*H*-indole-3-carbonitrile;~~

~~1-[3-(4-butyl-piperidin-1-yl)-propyl]-5,6-dimethyl-1*H*-benzoimidazole;~~

~~1-[3-(4-butyl-piperidin-1-yl)-propyl]-5(6)-dimethyl-1*H*-benzoimidazole;~~

~~1-[3-(4-butyl-piperidin-1-yl)-propyl]-5-methoxy-1*H*-benzoimidazole;~~

~~{1-[3-(4-butyl-piperidin-1-yl)-propyl]-1H-benzoimidazol-2-yl}-methanol;~~

~~1-[3-(4-butyl-piperidin-1-yl)-propyl]-2-trifuoromethyl-1*H*-benzoimidazole;~~

~~3-[3-(4-butyl-piperidine-1-yl)-propyl]-1H-indazole, HCl;~~

~~3-[3-(4-butyl-piperidine-1-yl)-propyl]-5-nitro-1H-indazole;~~

~~3-[3-(4-butyl-piperidine-1-yl)-propyl]-5,7-dinitro-1H-indazole;~~

3-[3-(4-butyl-piperidin-1-yl)-propyl]-benzo[*d*]isothiazole[[;]].

~~3-[3-(4-butyl-piperidin-1-yl)-propyl]-5-methoxy-1H-indazole;~~

~~3-[3-(4-butyl-piperidin-1-yl)-propyl]-4-methoxy-1H-indazole~~

~~3-[3-(4-butyl-piperidin-1-yl)-propyl]-6-methoxy-1H-indazole;~~

~~3-[3-(4-butyl-piperidin-1-yl)-propyl]-1H-indazole-4-ol;~~

~~3-[3-(4-butyl-piperidin-1-yl)-propyl]-1H-indazole-6-ol; or~~

~~3-[3-(4-butyl-piperidin-1-yl)-propyl]-1H-indazole-5-ol.~~

9 18. (CURRENTLY AMENDED) A pharmaceutical composition comprising an effective amount of a compound of formula (I):



(I)

wherein:

Z_1 is CR_1, Z_2 is CR_2, Z_3 is CR_3, and Z_4 is CR_4;

W_1 is [[O,]] S[[, or NR_5]], W_2 is N or CR_6, and W_3 is CG; ~~W_1 is NG, W_2 is CR_5 or N, and W_3 is CR_6 or N;~~

G is of formula (II):



(II)

Y is O, S, CHOH, -NHC(O)-, -C(O)NH-, -C(O)-, -OC(O)-, -(O)CO-, $-NR_7$-, -CH=N-, or absent;

p is 1, 2, 3, 4 or 5;

Z is CR_8R_9 or absent;

each t is 1, 2, or 3;

each R_1, R_2, R_3, and R_4, independently, is H, amino, hydroxyl, halo, or straight- or branched-chain C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, ~~C_{1-6} heteroalkyl,~~ methoxymethyl, ethoxymethyl, propoxymethyl C_{1-6} haloalkyl, -CN, $-CF_3$, $-OR_{11}$, $-COR_{11}$, $-NO_2$, $-SR_{11}$, $-NHC(O)R_{11}$, $-C(O)NR_{12}R_{13}$, $-NR_{12}R_{13}$, $-NR_{11}C(O)NR_{12}R_{13}$, $-SO_2NR_{12}R_{13}$, $-OC(O)R_{11}$, $-O(CH_2)_qNR_{12}R_{13}$, or $-(CH_2)_qNR_{12}R_{13}$, where q is an integer from 2 to 6, or R_1 and R_2 together form -NH-N=N- or R_3 and R_4 together form -NH-N=N-;

each R_5, R_6, and R_7, independently, is H, C_{1-6} alkyl; formyl; C_{3-6} cycloalkyl; C_{5-6} aryl, optionally substituted with halo or C_{1-6} alkyl; or C_{5-6} heteroaryl, optionally substituted with halo or C_{1-6} alkyl;

each R_8 and R_9, independently, is H or straight- or branched-chain C_{1-8} alkyl;

R_{10} is [[H,]] straight- or branched-chain C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-8} alkylidene, C_{1-8} alkoxy, methoxymethyl, ethoxymethyl, propoxymethyl or ~~C_{1-8} heteroalkyl, C_{1-8} aminoalkyl, C_{1-8} haloalkyl, C_{1-8} alkoxycarbonyl,~~

~~C_{1-8} hydroxyalkoxy, C_{1-8} hydroxyalkyl, SH, C_{1-8} alkylthio, O CH_2 C_{5-6} aryl, C(O) C_{5-6} aryl substituted with C_{1-3} alkyl or halo, C_{5-6} aryl, C_{5-6} cycloalkyl, C_{5-6} heteroaryl, C_{5-6} heterocycloalkyl, $NR_{12}R_{13}$, $C(O)NR_{12}R_{13}$, $NR_{11}C(O)NR_{12}R_{13}$, $CR_{11}R_{12}R_{13}$, $OC(O)R_{11}$, $(O)(CH_2)_sNR_{12}R_{13}$ or $(CH_2)_sNR_{12}R_{13}$, s being an integer from 2 to 8~~;

R_{10}' is H, straight- or branched-chain C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-8} alkylidene, C_{1-8} alkoxy, ~~C_{1-8} heteroalkyl~~, methoxymethyl, ethoxymethyl, propoxymethyl C_{1-8} aminoalkyl, C_{1-8} haloalkyl, C_{1-8} alkoxycarbonyl, C_{1-8} hydroxyalkoxy, C_{1-8} hydroxyalkyl, or C_{1-8} alkylthio;

each R_{11}, independently, is H, straight- or branched-chain C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, ~~C_{2-8} heteroalkyl~~, methoxymethyl, ethoxymethyl, propoxymethyl C_{2-8} aminoalkyl, C_{2-8} haloalkyl, C_{1-8} alkoxycarbonyl, C_{2-8} hydroxyalkyl, -C(O)-C_{5-6} aryl substituted with C_{1-3} alkyl or halo, C_{5-6} aryl, C_{5-6} heteroaryl, C_{5-6} cycloalkyl, C_{5-6} heterocycloalkyl, $-C(O)NR_{12}R_{13}$, $-CR_5R_{12}R_{13}$, $-(CH_2)_tNR_{12}R_{13}$, t is an integer from 2 to 8; and

each R_{12} and R_{13}, independently, is H, C_{1-6} alkyl; C_{3-6} cycloalkyl; C_{5-6} aryl, optionally substituted with halo or C_{1-6} alkyl; or C_{5-6} heteroaryl, optionally substituted with halo or C_{1-6} alkyl; ~~or R_{12} and R_{13} together form a cyclic structure;~~

or a pharmaceutically acceptable salt, ester or prodrug thereof.

10 ~~19~~. (CURRENTLY AMENDED) A pharmaceutical composition of Claim 18, wherein each t is 2 ~~and R_{10} is straight- or branched-chain C_{2-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-8} alkylidene, C_{1-8} alkoxy, or C_{1-8} heteroalkyl~~.

11 ~~20~~. (ORIGINAL) A pharmaceutical composition of Claim 19, wherein R_{10} is n-butyl.

21. (CANCELED)

12 ~~22~~. (PREVIOUSLY PRESENTED) A pharmaceutical composition of Claim 19, wherein each R_1, R_2, R_3, and R_4, independently, is H, hydroxyl, halo, ~~C_{1-6}heteroalkyl~~, methoxymethyl, ethoxymethyl, propoxymethyl CF_3, $-NO_2$, or straight- or branched-chain C_{1-6} alkyl, or R_1 and R_2 together form -NH-N=N- or R_3 and R_4 together form -NH-N=N-.

13 ~~23~~. (ORIGINAL) A pharmaceutical composition of Claim 19, wherein Y is absent or O, p is 0, 1, 2 or 3, and R_8 and R_9 are H.

14 ~~24~~. (ORIGINAL) A pharmaceutical composition of Claim 23, wherein Z is absent, Y is absent and p is 3.

15 ~~25~~. (ORIGINAL) A pharmaceutical composition of Claim 24, wherein R_{10} is n-butyl.

26-33. (CANCELED)

16 34. (CURRENTLY AMENDED) A pharmaceutical composition of Claim 19, wherein the compound is:

~~1-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indole;~~

~~1-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-benzoimidazole;~~

~~3-methyl-1-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indole;~~

~~5-bromo-1-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indole;~~

~~3-formyl-1-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indole;~~

~~7-bromo-1-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indole;~~

~~3-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-benzo[*d*]isoxazole;~~

~~3-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indole;~~

~~3-(2-(4-*n*-butylpiperidine)-1-yl-ethyl)-1*H*-indole;~~

~~3-(3-(4-*n*-butylpiperidine)-1-yl-propyl)-1*H*-indazole;~~

~~3-(2-(4-n-butylpiperidine)-ethoxy)-7-methyl-benzo[*d*]isoxazole;~~

~~1-(3-(4-methylpiperidine)-1-yl-propyl)-1H-indazole;~~

~~1-(3-(4-pentylpiperidine)-1-yl-propyl)-1H-indazole;~~

~~1-(3-(4-propylpiperidine)-1-yl-propyl)-1H-indazole;~~

~~1-(3-(4-(3-methyl-butyl)-piperidine)-1-yl-propyl)-1H-indazole~~

~~1-(3-(4-pentylidene-piperidine)-1-yl-propyl)-1H-indazole;~~

~~1-(3-(4-propylidene-piperidine)-1-yl-propyl)-1H-indazole~~

1-benzo[*b*]thiophen-2-yl-4-(4-butylpiperidin-1-yl)-butan-1-one

~~4-(4-butylpiperidin-1-yl)-1-(3-methyl-benzofuran-2-yl)-butan-1-one;~~

4-(4-butylpiperidin-1-yl)-1-(5-fluoro-3-methyl-benzo[*b*]thiophen-2-yl)-butan-1-one;

~~1-benzofuran-2-yl-4-(4-butylpiperidin-1-yl)-butan-1-one;~~

1-(3-bromo-benzo[*b*]thiophen-2-yl)-4-(4-butylpiperidin-1-yl)-butan-1-one

1-(3-benzo[*b*]thiophen-2-yl-propyl)-4-butylpiperidine;

~~1-(3-benzofuran-2-yl-propyl)-4-butylpiperidine;~~

~~4-butyl-1-[3-(3-methyl-benzofuran-2-yl)-propyl]-piperidine;~~

4-butyl-1-[3-(5-fluoro-3-methyl-benzo[*b*]thiophen-2-yl)-propyl]-piperidine;

~~2-(3-iodo-propyl)-benzo[*b*]thiophene;~~

1-(3-benzo[*b*]thiophen-2-yl-propyl)-4-methylpiperidine

1-(3-benzo[*b*]thiophen-2-yl-propyl)-4-benzylpiperidine; or

~~1-(3-benzo[*b*]thiophen-2-yl-propyl)-4-(2-methoxy-phenyl)-piperidine;~~

~~1-[3-(4-butylpiperidin-1-yl)-propyl]-1H-benzotriazole;~~

~~1-[3-(4-butylpiperidin-1-yl)-propyl]-1*H*-indole-3-carbaldehyde;~~

~~{1-[3-(4-butylpiperidin-1-yl)-propyl]-1H-indol-3-yl}-methanol;~~

~~1-[3-(4-butylpiperidin-1-yl)-propyl]-2-phenyl-1*H*-benzoimidazole;~~

~~1-[3-(4-butylpiperidin-1-yl)-propyl]-3-chloro-1*H*-indazole;~~

~~1-[3-(4-butylpiperidin-1-yl)-propyl]-6-nitro-1*H*-indazole;~~

~~3-[2-(4-butylpiperidin-1-yl)-ethoxy]-benzo[*d*]isoxazol;~~

~~3-[3-(4-butyl-piperidin-1-yl)-propyl]-1*H*-indole hydrochloride;~~

~~1H-indazole-3-carboxylic acid-(2-(4-butylpiperidin)-1-yl-ethyl)-amide;~~

~~1-[3-(4-butylpiperidin-1-yl)-propyl]-5-nitro-1H-indazole;~~

~~1-[3-(4-butyl-piperidin-1-yl)-propyl]-2-methyl-1*H*-indole;~~

~~1-{1-[3-(4-butyl-piperidin-1-yl)-propyl]-1H-indol-3-yl}-ethanone;~~

~~{1-[3-(4-butyl-piperidin-1-yl)-propyl]-1H-indol-3-yl}-acetonitrile;~~

~~1-[3-(4-butyl-piperidin-1-yl)-propyl]-1*H*-indole-3-carbonitrile;~~

~~1-[3-(4-butyl-piperidin-1-yl)-propyl]-5,6-dimethyl-1*H*-benzoimidazole;~~

~~1-[3-(4-butyl-piperidin-1-yl)-propyl]-5(6)-dimethyl-1*H*-benzoimidazole;~~

~~1-[3-(4-butyl-piperidin-1-yl)-propyl]-5-methoxy-1*H*-benzoimidazole;~~

~~{1-[3-(4-butyl-piperidin-1-yl)-propyl]-1H-benzoimidazol-2-yl}-methanol;~~

~~1-[3-(4-butyl-piperidin-1-yl)-propyl]-2-trifuoromethyl-1*H*-benzoimidazole;~~

~~3-[3-(4-butyl-piperidine-1-yl)-propyl]-1H-indazole, HCl;~~

~~3-[3-(4-butyl-piperidine-1-yl)-propyl]-5-nitro-1H-indazole;~~

~~3-[3-(4-butyl-piperidine-1-yl)-propyl]-5,7-dinitro-1H-indazole;~~

3-[3-(4-butyl-piperidin-1-yl)-propyl]-benzo[*d*]isothiazole[[;]].

~~3-[3-(4-butyl-piperidin-1-yl)-propyl]-5-methoxy-1H-indazole;~~

~~3-[3-(4-butyl-piperidin-1-yl)-propyl]-4-methoxy-1H-indazole~~

~~3-[3-(4-butyl-piperidin-1-yl)-propyl]-6-methoxy-1H-indazole;~~

~~3-[3-(4-butyl-piperidin-1-yl)-propyl]-1H-indazole-4-ol;~~

~~3-[3-(4-butyl-piperidin-1-yl)-propyl]-1H-indazole-6-ol; or~~

~~3-[3-(4-butyl-piperidin-1-yl)-propyl]-1H-indazole-5-ol.~~

35-76. (CANCELED)